Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AKER

Akers Biosciences (AKER) Stock Price, News & Analysis

Akers Biosciences logo

About Akers Biosciences Stock (NASDAQ:AKER)

Advanced Chart

Key Stats

Today's Range
$0.11
$0.13
50-Day Range
$2.47
$4.59
52-Week Range
$1.65
$6.97
Volume
5.36 million shs
Average Volume
769,876 shs
Market Capitalization
$2.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.

Receive AKER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AKER Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Cam Akers Not Worth A Look In Week 10
See More Headlines

AKER Stock Analysis - Frequently Asked Questions

Akers Biosciences, Inc. (NASDAQ:AKER) released its earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) EPS for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akers Biosciences investors own include Sorrento Therapeutics (SRNE), Aytu BioPharma (AYTU), ImmunoGen (IMGN), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Vaxart (VXRT) and Neovasc (NVCN).

Company Calendar

Last Earnings
11/15/2018
Today
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
NASDAQ:AKER
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.89 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.58 million
Price / Cash Flow
N/A
Book Value
$5.38 per share
Price / Book
0.02

Miscellaneous

Free Float
N/A
Market Cap
$2.16 million
Optionable
Not Optionable
Beta
0.30
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:AKER) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners